

MATERIAL SAFETY DATA SHEET



Consumer Care Division
 Bayer Corporation, 1884 Miles Avenue, Elkhart, IN 46514
 219 264 -8400

For accidental ingestion, or medical
 emergency, call 1-800-800-4793

HMIS Code		
Health	1	Fire 0
Reactivity	0	Pers. Prot. 0

SECTION 1 - IDENTITY

Common Name: (used on label)

(Trade Name & Synonyms) Original ALKA-SELTZER Antacid & Pain Reliever

Product Code: 4028, 4002
 4024, 4022, 4019
 4017, 4012, 4011

Chemical Name:
 Active Ingredients: Aspirin 325 mg, Sodium Bicarbonate
 1916 mg, Citric Acid 1000 mg (See Section 8).

Chemical Family	Formula	CAS No.
None	Effervescent mixture.	None

SECTION 2 - HAZARDOUS INGREDIENTS

Hazardous Components - (chemical & common names)	Hazard	TLV Units
Aspirin	Ingestion (oral LD50 in rats = 5g or greater/kg).	

For additional information see Section 4.

SECTION 3 - PHYSICAL & CHEMICAL CHARACTERISTICS (Fire & Explosion Data)

Boiling Point	Specific Gravity (H ₂ O = 1)	Vapor Pressure (mm hg)
Not applicable.	Not applicable.	Not applicable.
Percent Volatile by Volume (%)	Vapor Density (Air = 1)	Evaporation Rate (= 1)
Not applicable.	Not applicable.	Not applicable.
Solubility in Water	Reactivity in Water/Air	
Not applicable.	Effervesces in contact with water, producing CO ₂ .	
Appearance and Odor	Effervescent white tablet.	
Flash Point	Flammable Limits in Air % by Volume	Auto-ignition Temperature
Not applicable.	Lower Upper	Not applicable.
	Not applicable.	
Extinguisher Media	Water	
Special Fire Fighting Procedures	None	
Unusual Fire and Explosion Hazards	None	

SECTION 4 - HEALTH HAZARDS

OSHA Permissible Exposure Limit	ACGIH Threshold Limit Value
Not established.	Not established.
Other Exposure Limit Used	FDA - Aspirin 4000 mg/24 hrs for 10 days in a 70 kg person; acute toxicity may follow ingestions of 150 mg/kg.
Signs and Symptoms - Acute Overexposure	Nausea, vomiting, ringing in the ears, fever, coma, respiratory alkalosis, metabolic acidosis, convulsions (see Section 8).
Signs and Symptoms - Chronic Overexposure	Ringing in the ears, diminished hearing, confusion, agitation, lethargy, pulmonary edema, cardiovascular collapse (see Section 8).
Medical Conditions Generally Aggravated by Exposure	Ulcers (aspirin), asthma (aspirin), predisposition to bleeding & decreased platelet function (aspirin), congestive heart failure (sodium), hypertension (sodium).
Primary Route(s) of Exposure	Oral
Emergency and First Aid Procedures	Contact your regional poison control center or physician immediately. Additional information may be obtained by contacting Bayer Corporation at 1-800-800-4793
Hygienic Practices	Normal clinical.
Chemical Listed as Carcinogen or Potential Carcinogen	None

Common Name: Original ALKA-SELTZER Antacid & Pain Reliever

SECTION 5 - PHYSICAL HAZARDS

Stability: Unstable Conditions to avoid
Stable

Incompatibility
(Materials to Avoid) None

Hazardous
Decomposition Products None

Hazardous Polymerization May Occur Conditions to Avoid
Will Not Occur

SECTION 6 - SPECIAL PROTECTION INFORMATION

Respiratory Protection
None for normal use.

Ventilation None for normal use. Work Practices
Not applicable.

Protective Gloves None for normal use. Eye Protection
None for normal use.

Other Protective
Clothing or Equipment None for normal use.

SECTION 7 - SPECIAL PRECAUTIONS AND SPILL/LEAK PROCEDURES

Precautions to be Taken
in Handling and Storage
None

Steps to be Taken in Case
Material is Released or Spilled
Contain for disposal.


Waste Disposal
Methods
Dispose as normal solid waste.

SECTION 8 - ADDITIONAL INFORMATION

Alka-Seltzer in water contains principally the antacid sodium citrate and the analgesic sodium acetylsalicylate.

Classic signs and symptoms of acute and chronic salicylate overdose are listed in Section 4. However, studies indicate that plasma salicylate will not reach toxic levels following ingestion of highly buffered aspirin in solution, regardless of the dose taken. This is due to alkalization of the urine by the citrate buffer which increases the excretion of salicylate. Therefore, the classic signs and symptoms of salicylate toxicity listed in Section 4 may not be seen with overdose of this product.

Signature of Person
Responsible for Preparation


Dieter Neuser, M.D., Ph.D.

Date
Prepared March 1991

Telephone No.
219/264-8142

Date
Revised November 1991

The opinions expressed herein are those of qualified experts within Bayer Corporation. We believe that the information contained herein is current as of the date of this Material Safety Data Sheet. Since the use of this information and these opinions and the conditions of the product are not within the control of Bayer Corporation, it is the user's obligation to determine the conditions of safe use of the product.



MATERIAL SAFETY DATA SHEET

BAYER CORPORATION
CONSUMER CARE DIVISION
36 Columbia Road
Morristown, NJ 07962-1910

TRANSPORTATION EMERGENCY
CALL CHEMTREC: 800-424-9300
INTERNATIONAL: 703-527-3887

NON-TRANSPORTATION
BAYER EMERGENCY PHONE...: (800) 743-5423
BAYER INFORMATION PHONE.: (800) 743-5423

1. CHEMICAL PRODUCT IDENTIFICATION:

PRODUCT NAME.....: Original Bayer (R) Aspirin
PRODUCT CODE.....: 114,110,111,117,112,120,113,181
CHEMICAL FAMILY.....: Analgesic

2. COMPOSITION/INFORMATION ON INGREDIENTS:

INGREDIENT NAME /CAS NUMBER EXPOSURE LIMITS CONCENTRATION (%)

***** HAZARDOUS INGREDIENTS *****

This pharmaceutical product, available without a prescription, is for human use. These materials are not subject to the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200.

***** OTHER INGREDIENTS *****

Aspirin
50-78-2 OSHA : 5.00 mg/m3 TWA Greater than 25 %
ACGIH: 5.00 mg/m3 TWA
* See Section 3 for potential health effects.

3. HAZARDS IDENTIFICATION:

```

*****
*                                     *
*                               EMERGENCY OVERVIEW                               *
*                                     *
* Color: White; Form: Solid; Tablets/Caplets; Odor: Slight                    *
* acidic; Product poses little or no hazard if spilled and no                 *
* unusual hazard if involved in a fire; See Potential Health                 *
* Effects if the recommended dosage is exceeded.                             *
*****

```

POTENTIAL HEALTH EFFECTS:

ROUTE(S) OF ENTRY.....: Appropriate route of entry: oral

HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE:

NOTE: This is a pharmaceutical material available without a prescription - use only as directed. See product packaging for further information concerning adverse effects and drug interaction precautions.

ACUTE EFFECTS OF EXPOSURE.....: Acute overexposure to this product may cause rapid or deep breathing, confusion, agitation, nausea, vomiting, diminished hearing, ringing in the ears, hemorrhage, acid/base imbalances, coma, seizures, hypotension or cardiac arrhythmias. Allergic reactions are possible with symptoms of reddening, itching, rash, swelling of the face, throat or tongue, and breathing problems. If swelling of the face, throat, tongue or breathing problems occur, seek medical attention immediately.

CHRONIC EFFECTS OF EXPOSURE....: Chronic overexposure to this product may cause effects described under acute exposure. In addition, liver and/or kidney dysfunction may result.

CARCINOGENICITY.....: The components of this product are not listed by NTP, IARC or regulated as a carcinogen by OSHA.

MEDICAL CONDITIONS

AGGRAVATED BY EXPOSURE.....: Persons with asthma, preexisting hypersensitivity to the components of this product or other pain releivers, young children, the elderly, and pregnant women may be more susceptible to the effects of this product. In addition, children and teenagers with chickenpox or flu symptoms, persons who are at risk for hemorrhage, those with a history of gastrointestinal ulcers or bleeding, who have impaired renal function, who are taking other prescription medications, or who consume more than 3 alcohol containing drinks per day may also be more susceptible to the effects of this product.

EXPOSURE LIMITS.....: FDA -- Aspirin 4000 mg/24 hrs. for 10 days in a 70 kg person; acute toxicity may follow ingestions of 150 mg/kg.

4. FIRST AID MEASURES:

FIRST AID FOR EYES.....: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Call a physician.
FIRST AID FOR SKIN.....: Flush skin with plenty of soap and water. Contact a physician if irritation develops.
FIRST AID FOR INHALATION: Not applicable.
FIRST AID FOR INGESTION.: In case of overdose, contact your regional poison control center or physician immediately. For additional information, contact Bayer Corporation at 1-800-800-4793.

5. FIRE FIGHTING MEASURES:

FLASH POINT.....: Not Applicable
AUTO-IGNITION TEMPERATURE.....: Not Applicable
EXTINGUISHING MEDIA.....: Water
SPECIAL FIRE FIGHTING PROCEDURES: Firefighters should be equipped with self-contained breathing apparatus to protect against potentially toxic and irritating fumes.

6. ACCIDENTAL RELEASE MEASURES:

SPILL OR LEAK PROCEDURES.....: Spills should be swept up and placed in appropriate containers for disposal. Avoid creating dusty conditions.

7. HANDLING AND STORAGE:

STORAGE TEMPERATURE(MIN/MAX): Room temperature.
SHELF LIFE.....: Do not use after expiration date.
SPECIAL SENSITIVITY.....: None known.
HANDLING/STORAGE PRECAUTIONS: Keep this and all drugs out of the reach of children. Avoid contact with eyes and skin. Wash thoroughly after handling. Store in a dry place away from excessive heat. Reseal containers immediately after use. Use normal precautions for storage of a drug.

8. PERSONAL PROTECTION;

EYE PROTECTION REQUIREMENTS.....: None for normal use.
SKIN PROTECTION REQUIREMENTS.....: None for normal use.
VENTILATION REQUIREMENTS.....: Under normal conditions of use, special
ventilation is not required.
RESPIRATOR REQUIREMENTS.....: Under normal conditions of use,
respiratory protection is not required.
WORK PRACTICES.....: Normal clinical practice. Use good
personal hygiene - wash hands and exposed skin thoroughly with soap and
water after each use.
ADDITIONAL PROTECTIVE MEASURES.....: Employers shall provide handwashing
facilities which are readily accessible to employees. Educate and train
employees in the safe use and handling of this product.

9. PHYSICAL AND CHEMICAL PROPERTIES;

PHYSICAL FORM.....: Solid
APPEARANCE.....: Tablets/Caplets
COLOR.....: White
ODOR.....: Slight acidic
PH.....: Not Established
BOILING POINT.....: Not Applicable
MELTING/FREEZING POINT.....: Not Applicable
SOLUBILITY IN WATER.....: Soluble
SPECIFIC GRAVITY.....: Not Established
BULK DENSITY.....: Not Established
VAPOR PRESSURE.....: Not Applicable

10. STABILITY AND REACTIVITY;

STABILITY.....: This is a stable material.
HAZARDOUS POLYMERIZATION...: Will not occur.
INCOMPATIBILITIES.....: See product packaging for drug interaction.
INSTABILITY CONDITIONS.....: None known.
DECOMPOSITION PRODUCTS.....: Not Applicable.

11. TOXICOLOGICAL INFORMATION:

TOXICITY DATA FOR: Aspirin

ACUTE TOXICITY

ORAL LD50.....: Greater than 1,500 mg/kg (rat)

12. ECOLOGICAL INFORMATION:

NO ECOLOGICAL INFORMATION AVAILABLE

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD.....: Waste disposal should be in accordance with existing federal, state and local environmental control laws.

14. TRANSPORTATION INFORMATION:

TECHNICAL SHIPPING NAME.....: Analgesic

PRODUCT LABEL.....: Original Bayer (R) Aspirin

DOT (DOMESTIC SURFACE)

HAZARD CLASS OR DIVISION: Non-Regulated

IMO / IMDG CODE (OCEAN)

HAZARD CLASS DIVISION NUMBER...: Non-Regulated

ICAO / IATA (AIR)

HAZARD CLASS DIVISION NUMBER...: Non-Regulated

15. REGULATORY INFORMATION:

OSHA STATUS.....: This material is not subject to the OSHA Hazard Communication Standard as noted in 29 CFR 1910.1200(b) (6) (vii).

Product Code: 114,110,111,117,112,120,113,181
Approval date: 04/10/2002

MSDS Page 5
Continued on next page

15. REGULATORY INFORMATION (Continued)

TSCA STATUS.....: This product is exempt from TSCA Regulation under Section 3 (2)(B)(vi) when used for pharmaceutical application.

CERCLA REPORTABLE QUANTITY...: None

SARA TITLE III:

SECTION 302 EXTREMELY HAZARDOUS SUBSTANCES...: None

SECTION 311/312 HAZARD CATEGORIES.....: Exempt from SARA Section 311/312

SECTION 313 TOXIC CHEMICALS.....: None

RCRA STATUS.....: If discarded in its purchased form, this product would not be a hazardous waste either by listing or by characteristic. However, under RCRA, it is the responsibility of the product user to determine at the time of disposal, whether a material containing the product or derived from the product should be classified as a hazardous waste. (40 CFR 261.20-24)

The following chemicals are specifically listed by individual states; other product specific health and safety data in other sections of the MSDS may also be applicable for state requirements. For details on your regulatory requirements you should contact the appropriate agency in your state.

COMPONENT NAME /CAS NUMBER	CONCENTRATION	STATE CODE
Aspirin 50-78-2	Greater than 25 %	PA1, CA , MA, NJ1
Corn starch 9005-25-8	10-25 %	PA1, MA, NJ4

CA = California Proposition 65
 MA = Massachusetts Hazardous Substance List
 NJ1 = New Jersey Hazardous Substance List
 NJ4 = New Jersey Other - included in 5 predominant ingredients > 1%
 PA1 = Pennsylvania Hazardous Substance List

ADDITIONAL INFORMATION: ACTIVE INGREDIENT (per tablet) Aspirin, 325 mg
 INACTIVE INGREDIENTS: Hydroxypropyl Methylcellulose, Starch, Triacetin.

16. OTHER INFORMATION:

HMIS RATINGS: Health 1 Flammability 0 Reactivity 0

Product Code: 114,110,111,117,112,120,113,181
 Approval date: 04/10/2002

MSDS Page 6
 Continued on next page

16. OTHER INFORMATION (Continued)

0=Minimal 1=Slight 2=Moderate 3=Serious 4=Severe

Bayer's method of hazard communication is comprised of Product Labels and Material Safety Data Sheets. HMIS ratings are provided by Bayer as a customer service.

REASON FOR ISSUE.....: Name Change;was Genuine Bayer (R) Aspirin
PREPARED BY.....: S. Van Volkenburg
APPROVED BY.....: Llew C. Williams
APPROVAL DATE.....: 04/10/2002
SUPERSEDES DATE.....: 06/12/1998
MSDS NUMBER.....: 34102

This information is furnished without warranty, expressed or implied, except that it is accurate to the best knowledge of Bayer Corporation. The data on this sheet relates only to the specific material designated herein. Bayer Corporation assumes no legal responsibility for use or reliance upon these data.

Product Code: 114,110,111,117,112,120,113,181
Approval date: 04/10/2002

MSDS Page 7
Last page



MATERIAL SAFETY DATA SHEET

BAYER CORPORATION
CONSUMER CARE DIVISION
36 Columbia Road
Morristown, NJ 07962-1910

TRANSPORTATION EMERGENCY CALL CHEMTREC: 800-424-9300
INTERNATIONAL: 703-527-3887
NON-TRANSPORTATION BAYER EMERGENCY PHONE...: (800) 743-5423
BAYER INFORMATION PHONE.: (800) 743-5423

1. CHEMICAL PRODUCT IDENTIFICATION:

PRODUCT NAME.....: Aleve
PRODUCT CODE.....: 501; 503; 505; 004
CHEMICAL FAMILY.....: Analgesic
NDC NUMBER.....: 0280-6010-24; 0280-6010-50; 0280-6010-01; 0280-6010-15

2. COMPOSITION/INFORMATION ON INGREDIENTS:

INGREDIENT NAME /CAS NUMBER EXPOSURE LIMITS CONCENTRATION (%)

***** HAZARDOUS INGREDIENTS *****

This pharmaceutical product, available without a prescription, is for human use. These materials are not subject to the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200. This Material Safety Data Sheet is not intended for industrial exposures.

3. HAZARDS IDENTIFICATION:

* EMERGENCY OVERVIEW *
* Color: Light blue; Form: Solid; Caplet; Odor: Odorless; *
* Product poses little or no hazard if spilled and no unusual *
* hazard if involved in a fire; See Potential Health Effects *
* if the recommended dosage is exceeded. *

POTENTIAL HEALTH EFFECTS:

Product Code: 501; 503; 505; 004
Approval date: 06/30/1997

MSDS Page 1
Continued on next page

3. HAZARDS IDENTIFICATION (Continued)

ROUTE(S) OF ENTRY.....: Appropriate route of entry: oral

HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE:

NOTE: This is a pharmaceutical material available without a prescription - use only as directed. See product packaging for further information concerning adverse effects and drug interaction precautions.

ACUTE EFFECTS OF EXPOSURE.....: Overdose may cause nausea, vomiting, confusion, ringing in the ears, irregular heartbeat, headache, drowsiness, and blood pressure effects.

CHRONIC EFFECTS OF EXPOSURE...: Chronic overexposure to this product may cause effects as described under acute exposure. An allergic reaction is possible with symptoms of reddening, rash, and itching.

CARCINOGENICITY.....: The components of this product are not listed by NTP, IARC or regulated as a carcinogen by OSHA.

MEDICAL CONDITIONS

AGGRAVATED BY EXPOSURE.....: Persons with preexisting hypersensitivity to the components of this product and pregnant women may be more susceptible to the effects of this product. Persons consuming alcohol may also be more susceptible to the effects of this product.

4. FIRST AID MEASURES:

FIRST AID FOR EYES.....: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Call a physician.

FIRST AID FOR SKIN.....: Flush skin with plenty of soap and water. Contact a physician if irritation develops.

FIRST AID FOR INHALATION: Not applicable.

FIRST AID FOR INGESTION.: In case of overdose, contact your regional poison control center or physician immediately. For additional information, contact Bayer Corporation at 1-800-800-4793.

5. FIRE FIGHTING MEASURES:

FLASH POINT.....: Not Applicable

EXTINGUISHING MEDIA.....: All extinguishing media are suitable.

SPECIAL FIRE FIGHTING PROCEDURES: Firefighters should be equipped with self-contained breathing apparatus to protect against potentially toxic and irritating fumes.

6. ACCIDENTAL RELEASE MEASURES:

SPILL OR LEAK PROCEDURES.....: Spills should be swept up and placed in appropriate containers for disposal. Avoid creating dusty conditions.

7. HANDLING AND STORAGE:

STORAGE TEMPERATURE (MIN/MAX): Room temperature.
SHELF LIFE.....: Do not use after expiration date.
SPECIAL SENSITIVITY.....: Avoid direct sunlight.
HANDLING/STORAGE PRECAUTIONS: Keep this and all drugs out of the reach of children. Avoid contact with eyes and skin. Wash thoroughly after handling. Store in a dry place away from excessive heat. Reseal containers immediately after use. Use normal precautions for storage of a drug.

8. PERSONAL PROTECTION:

EYE PROTECTION REQUIREMENTS.....: None for normal use.
SKIN PROTECTION REQUIREMENTS.....: None for normal use.
VENTILATION REQUIREMENTS.....: Under normal conditions of use, special ventilation is not required.
RESPIRATOR REQUIREMENTS.....: Under normal conditions of use, respiratory protection is not required.
WORK PRACTICES.....: Normal clinical practice. Use good personal hygiene - wash hands and exposed skin thoroughly with soap and water after each use.
ADDITIONAL PROTECTIVE MEASURES.....: Employers shall provide handwashing facilities which are readily accessible to employees. Educate and train employees in the safe use and handling of this product.

9. PHYSICAL AND CHEMICAL PROPERTIES:

PHYSICAL FORM.....: Solid
APPEARANCE.....: Caplet
COLOR.....: Light blue
ODOR.....: Odorless
pH.....: Not Established
BOILING POINT.....: Not Applicable
MELTING/FREEZING POINT.....: Not Applicable
SOLUBILITY IN WATER.....: Soluble

9. PHYSICAL AND CHEMICAL PROPERTIES (Continued)

SPECIFIC GRAVITY: Not Established
BULK DENSITY.....: Not Established
VAPOR PRESSURE: Not Applicable

10. STABILITY AND REACTIVITY:

STABILITY.....: This is a stable material.
HAZARDOUS POLYMERIZATION...: Will not occur.
INCOMPATIBILITIES.....: See product packaging and the Physicians' Desk
Reference (PDR) for drug interaction.
INSTABILITY CONDITIONS.....: None known.
DECOMPOSITION PRODUCTS.....: Not Applicable.

11. TOXICOLOGICAL INFORMATION:

NO ANIMAL TOXICITY INFORMATION AVAILABLE

12. ECOLOGICAL INFORMATION:

NO ECOLOGICAL INFORMATION AVAILABLE

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD.....: Waste disposal should be in accordance with
existing federal, state and local environmental control laws.

14. TRANSPORTATION INFORMATION:

TECHNICAL SHIPPING NAME.....: Analgesic
PRODUCT LABEL.....: Aleve

DOT (DOMESTIC SURFACE)

HAZARD CLASS OR DIVISION: Non-Regulated

14. TRANSPORTATION INFORMATION (Continued)

 DOT (continued)

IMO / IMDG CODE (OCEAN)

HAZARD CLASS DIVISION NUMBER...: Non-Regulated

ICAO / IATA (AIR)

HAZARD CLASS DIVISION NUMBER...: Non-Regulated

 15. REGULATORY INFORMATION:

OSHA STATUS.....: This material is not subject to the OSHA Hazard
 Communication Standard as noted in 29 CFR
 1910.1200(b)(6)(vii).

TSCA STATUS.....: This product is exempt from TSCA Regulation under
 Section 3.(2)(B)(vi) when used for pharmaceutical
 application.

CERCLA REPORTABLE QUANTITY...: None

SARA TITLE III:

SECTION 302 EXTREMELY

HAZARDOUS SUBSTANCES...: None

SECTION 311/312

HAZARD CATEGORIES.....: Exempt from SARA Section 311/312

SECTION 313

TOXIC CHEMICALS.....: None

RCRA STATUS.....: If discarded in its purchased form, this product
 would not be a hazardous waste either by listing
 or by characteristic. However, under RCRA, it is
 the responsibility of the product user to
 determine at the time of disposal, whether a
 material containing the product or derived from
 the product should be classified as a hazardous
 waste. (40 CFR 261.20-24)

ADDITIONAL INFORMATION: ACTIVE INGREDIENT (per caplet): Naproxen Sodium, 220
 mg. INACTIVE INGREDIENTS: Magnesium Stearate, Microcrystalline cellulose,
 Opadry, Povidone, Talc.

 16. OTHER INFORMATION:

HMIS RATINGS:

Health	Flammability	Reactivity
1	0	0
0=Minimal	1=Slight	2=Moderate
		3=Serious
		4=Severe

Product Code: 501; 503; 505; 004
 Approval date: 06/30/1997

MSDS Page 5
 Continued on next page

16. OTHER INFORMATION (Continued)

Bayer's method of hazard communication is comprised of Product Labels and Material Safety Data Sheets. HMIS ratings are provided by Bayer as a customer service.

REASON FOR ISSUE.....: Update format
PREPARED BY.....: R. Ruppel-Kerr
APPROVED BY.....: Llew C. Williams
APPROVAL DATE.....: 06/30/1997
SUPERSEDES DATE.....: 05/04/1995
MSDS NUMBER.....: 29404

This information is furnished without warranty, expressed or implied, except that it is accurate to the best knowledge of Bayer Corporation. The data on this sheet relates only to the specific material designated herein. Bayer Corporation assumes no legal responsibility for use or reliance upon these data.

Product Code: 501; 503; 505; 004
Approval date: 06/30/1997

MSDS Page 6
Last page